| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.13 | 0.008 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.1 | 0.03 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.078 | 0.1 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.065 | 0.1 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.076 | 0.1 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.051 | 0.3 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.057 | 0.3 |